ASLAN PHARMACEU/ADR (NASDAQ:ASLN) Receives Consensus Recommendation of “Buy” from Brokerages

ASLAN PHARMACEU/ADR (NASDAQ:ASLN) has earned a consensus broker rating score of 1.67 (Buy) from the three analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and two have issued a strong buy recommendation on the company. ASLAN PHARMACEU/ADR’s rating score has declined by 11.3% in the last three months as a result of various analysts’ upgrades and downgrades.

Analysts have set a twelve-month consensus price objective of $6.50 for the company and are predicting that the company will post ($0.20) EPS for the current quarter, according to Zacks. Zacks has also given ASLAN PHARMACEU/ADR an industry rank of 74 out of 256 based on the ratings given to related companies.

A number of equities analysts have recently commented on the stock. Zacks Investment Research downgraded shares of ASLAN PHARMACEU/ADR from a “buy” rating to a “hold” rating in a research note on Tuesday, April 2nd. HC Wainwright set a $9.00 target price on shares of ASLAN PHARMACEU/ADR and gave the company a “buy” rating in a research note on Wednesday, June 5th.

A hedge fund recently raised its stake in ASLAN PHARMACEU/ADR stock. Platinum Investment Management Ltd. increased its position in shares of ASLAN PHARMACEU/ADR (NASDAQ:ASLN) by 36.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 388,395 shares of the company’s stock after buying an additional 103,900 shares during the period. Platinum Investment Management Ltd. owned about 1.21% of ASLAN PHARMACEU/ADR worth $1,666,000 at the end of the most recent reporting period. 7.84% of the stock is owned by hedge funds and other institutional investors.

Shares of ASLN stock traded down $0.03 during mid-day trading on Friday, reaching $3.47. The company’s stock had a trading volume of 100 shares, compared to its average volume of 20,994. ASLAN PHARMACEU/ADR has a 12-month low of $2.51 and a 12-month high of $9.28. The company has a current ratio of 3.64, a quick ratio of 5.19 and a debt-to-equity ratio of 0.46. The company has a market cap of $113.69 million and a PE ratio of -2.48.

ASLAN PHARMACEU/ADR (NASDAQ:ASLN) last issued its earnings results on Monday, April 29th. The company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.07. The business had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $2.70 million. Equities research analysts expect that ASLAN PHARMACEU/ADR will post -0.73 EPS for the current fiscal year.


ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.

Read More: What is Put Option Volume?

Get a free copy of the Zacks research report on ASLAN PHARMACEU/ADR (ASLN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with's FREE daily email newsletter.